Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Gut Pathogens
Published in: Gut Pathogens 1/2010

Open Access 01-12-2010 | Commentary

Probiotic therapy - recruiting old friends to fight new foes

Author: Roy D Sleator

Published in: Gut Pathogens | Issue 1/2010

Login to get access

Abstract

Against a backdrop of increasing antibiotic resistance, and the emergence of new and evolving pathogens, clinicians are increasingly forced to consider alternative therapies - probiotics are one such alternative.
Appendix
Available only for authorised users
Literature
1.
MacLean RC, Hall AR, Perron GG, Buckling A: The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nat Rev Genet. 2010, 11: 405-414. 10.1038/nrg2778.CrossRefPubMed
2.
Joerger RD: Alternatives to antibiotics: bacteriocins, antimicrobial peptides and bacteriophages. Poult Sci. 2003, 82: 640-647.CrossRefPubMed
3.
Sleator RD, Hill C: Battle of the bugs. Science. 2008, 321: 1294-1295. 10.1126/science.321.5894.1294b.CrossRefPubMed
4.
Ohashi Y, Ushida K: Health-beneficial effects of probiotics: Its mode of action. Anim Sci J. 2009, 80: 361-371. 10.1111/j.1740-0929.2009.00645.x.CrossRefPubMed
5.
Sleator RD, Hill C: New frontiers in probiotic research. Lett Appl Microbiol. 2008, 46: 143-147. 10.1111/j.1472-765X.2007.02293.x.CrossRefPubMed
6.
Callaway TR, Edrington TS, Anderson RC, Harvey RB, Genovese KJ, Kennedy CN, Venn DW, Nisbet DJ: Probiotics, prebiotics and competitive exclusion for prophylaxis against bacterial disease. Anim Health Res Rev. 2008, 9: 217-225. 10.1017/S1466252308001540.CrossRefPubMed
7.
Asaduzzaman SM, Sonomoto K: Lantibiotics: diverse activities and unique modes of action. J Biosci Bioeng. 2009, 107: 475-487. 10.1016/j.jbiosc.2009.01.003.CrossRefPubMed
8.
Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl HG: Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem. 2001, 276: 1772-1779.CrossRefPubMed
9.
Sang Y, Blecha F: Antimicrobial peptides and bacteriocins: alternatives to traditional antibiotics. Anim Health Res Rev. 2008, 9: 227-235. 10.1017/S1466252308001497.CrossRefPubMed
10.
Culligan EP, Hill C, Sleator RD: Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog. 2009, 1: 19-10.1186/1757-4749-1-19.PubMedCentralCrossRefPubMed
11.
Sleator RD, Watson D, Hill C, Gahan CG: The interaction between Listeria monocytogenes and the host gastrointestinal tract. Microbiology. 2009, 155: 2463-2475. 10.1099/mic.0.030205-0.CrossRefPubMed
12.
Bezkorovainy A: Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr. 2001, 73: 399S-405S.PubMed
13.
Sleator RD, Hill C: Patho-biotechnology: using bad bugs to do good things. Curr Opin Biotechnol. 2006, 17: 211-216.CrossRefPubMed
14.
Sleator RD, Hill C: 'Bioengineered Bugs' - a patho-biotechnology approach to probiotic research and applications. Med Hypotheses. 2008, 70: 167-169. 10.1016/j.mehy.2007.03.008.CrossRefPubMed
15.
Sleator RD, Hill C: Rational design of improved pharmabiotics. J Biomed Biotechnol. 2009, 2009: 87-2752.CrossRef
16.
Sheehan VM, Sleator RD, Hill C, Fitzgerald GF: Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain Bifidobacterium breve UCC2003. Microbiology. 2007, 153: 3563-3571. 10.1099/mic.0.2007/006510-0.CrossRefPubMed
17.
Watson D, Sleator RD, Hill C, Gahan CG: Enhancing bile tolerance improves survival and persistence of Bifidobacterium and Lactococcus in the murine gastrointestinal tract. BMC Microbiol. 2008, 8: 176-10.1186/1471-2180-8-176.PubMedCentralCrossRefPubMed
18.
Sleator RD, Hill C: Designer probiotics: a potential therapeutic for Clostridium difficile?. J Med Microbiol. 2008, 57: 793-794. 10.1099/jmm.0.47697-0.CrossRefPubMed
19.
20.
Paton AW, Morona R, Paton JC: Receptor-mimic probiotics: potential therapeutics for bacterial toxin-mediated enteric diseases. Expert Rev Gastroenterol Hepatol. 2010, 4: 253-255. 10.1586/egh.10.30.CrossRefPubMed
21.
Liu JJ, Reid G, Jiang Y, Turner MS, Tsai CC: Activity of HIV entry and fusion inhibitors expressed by the human vaginal colonizing probiotic Lactobacillus reuteri RC-14. Cell Microbiol. 2007, 9: 120-130. 10.1111/j.1462-5822.2006.00772.x.CrossRefPubMed
22.
Amdekar S, Dwivedi D, Roy P, Kushwah S, Singh V: Probiotics: multifarious oral vaccine against infectious traumas. FEMS Immunol Med Microbiol. 2010, 58: 299-306.PubMed
Metadata
Title
Probiotic therapy - recruiting old friends to fight new foes
Author
Roy D Sleator
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2010
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/1757-4749-2-5

Other articles of this Issue 1/2010

Gut Pathogens 1/2010 Go to the issue

Review

Helicobacter pylori: a poor man's gut pathogen?

Letter to the Editor

Compatible solutes: the key to Listeria's success as a versatile gastrointestinal pathogen?

Commentary

Ulcerative colitis and Crohn's disease: is Mycobacterium avium subspecies paratuberculosis the common villain?

Research

Isolation and detection of Mycobacterium avium subsp. paratuberculosis (MAP) from cattle in Ireland using both traditional culture and molecular based methods

Hypothesis

Stress-induced survival strategies enable Salmonella Enteritidis to persistently colonize the chicken oviduct tissue and cope with antimicrobial factors in egg white: A hypothesis to explain a pandemic

Research

Campylobacter jejuni induces transcytosis of commensal bacteria across the intestinal epithelium through M-like cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits